BREAKING: Study in Mexico Finds Cannabis Oil an Effective Treatment for Children with Rare Epilepsy

On March 14, 2017, Dr. Saul Garza Morales held a media conference in Mexico City, Mexico to reveal the positive results from his recent study on children with Lennox-Gastaut Syndrome that found Real Scientific Hemp Oil-X™ (RSHO-X™) to be a beneficial and therapeutic treatment for children suffering from the symptoms of this severe epileptic disorder.

The study, which was conducted by renowned Mexican physician Dr. Saul Garza Morales, included 39 patients with LGS, which is a severe form of pediatric epilepsy that typically develops in children before the age of four.

Of those 39 patients, which took up to 5-7mg CBD/kg progressive doses of the Company’s RSHO-X™ 5000MG, 84 percent experienced reduction in motor seizures; 53 percent reported better than a 75 percent reduction in seizures; and 17 percent (7 cases) reported a full elimination of all seizures over a four-month period, with zero patients reporting any side effects.

“The results of this study are very exciting as they show the best results of any product/medication ever recorded regarding the reduction of seizures in Lenno
x-Gastaut Syndrome patients, with 7 of the patients in the study experiencing 100 percent relief from their seizures,” said Dr. Stuart Titus, Chief Executive Officer of Medical Marijuana, Inc.

Prior to this encouraging study news, children with such a severe form of epilepsy were offered a bleak diagnosis that offered no signs of beneficial treatment, once the epilepsy moved to the refractory (drug resistant) phase. However, this study now gives children an option for relief with RSHO-X™.

Dr. Garza’s Lennox-Gastaut study also showed twice the efficacy in seizure reduction as per GW Pharmaceuticals’, a London-based developer of cannabinoid-based medicines, product Epidolex, with zero side effects. In contrast, 79 percent of children in GW’s Epidiolex study reported suffering adverse effects and 30 percent suffered severe adverse events. Overall, studies like the one conducted by Dr. Garza are vital, as they will continue to help fuel less restrictive medical cannabis programs not only in Mexico, but across the globe, according to Dr. Titus.

HempMeds® Mexico is the first company to have a medical cannabis product approved for import into Mexico. Patients can legally import the CBD hemp oil by obtaining a doctor’s prescription and import certificate from the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS). Doctors can prescribe RSHO-X™ for any condition, disease, or disorder, and so far HempMeds® Mexico has helped over 260 children with epilepsy challenges alone.

In a recent statement, Dr. Saul Garza said that with the conclusion of his research study on Lennox-Gastaut patients in Mexico, he is now hoping to further bring the benefits to people suffering from autism and is currently enrolling patients for a new study on the effects of cannabidiol (CBD) on autism. Results of Garza’s Lennox-Gastaut study are set to be published in the near future. You can read the entire study abstract here.

Watch the entire live streamed press conference